One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC
Cancer Cell · 2026-11 · 44 (11) · 2115-2117
DOI: 10.1016/j.ccell.2026.08.003 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2026-11. Verfasst von Derek De-Rui Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Protein Kinase Inhibitors. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Pathology, College of Medicine…
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: chihyang@ntu.edu.tw.
Zitieren
APA
Huang, D. D., & Yang, J. C. (2026). One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC. Cancer Cell, 44(11), 2115-2117. https://doi.org/10.1016/j.ccell.2026.08.003
Vancouver
Huang DD, Yang JC. One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC. Cancer Cell. 2026;44(11):2115-2117. doi:10.1016/j.ccell.2026.08.003
BibTeX
@article{Huang2026,
author = {Huang, Derek De-Rui and Yang, James Chih-Hsin},
title = {One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {11},
pages = {2115--2117},
doi = {10.1016/j.ccell.2026.08.003}
}
EUVIMED